Vanguard Group Inc Phase Bio Pharmaceuticals Inc Transaction History

Vanguard Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.52 - $1.59 $9,377 - $28,672	-18,033 Reduced 0.99%	1,808,098 $1.09 Million
Q1 2022 May 13, 2022	SELL	$0.97 - $2.66 $8,508 - $23,333	-8,772 Reduced 0.48%	1,826,131 $2.41 Million
Q4 2021 Feb 14, 2022	SELL	$1.9 - $4.05 $75,373 - $160,663	-39,670 Reduced 2.12%	1,834,903 $4.79 Million
Q3 2021 Nov 12, 2021	BUY	$2.72 - $3.85 $16,072 - $22,749	5,909 Added 0.32%	1,874,573 $5.83 Million
Q2 2021 Aug 13, 2021	BUY	$2.7 - $3.98 $5.05 Million - $7.44 Million	1,868,664 New	1,868,664 $6.95 Million

Ticker PHAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,858,100
Description
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or li...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.